Adagene Inc (ADAG NASDAQ) stock market data APIs
$1.8287
-0.03(-1.6%)
as of December 19, 2025
Try our APIs with
free plan!
Adagene Inc Financial Data Overview
Price chart is built with
Anychart
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Prev. Close
1.8287
Open
1.7956
High
1.9173
Low
1.7878
52 wk Range
1.3-3.16
Market Cap
84 836 K
Shares Outstanding
47 131 K
Revenue
103 K
EPS
0
Beta
0.728
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adagene Inc data using free add-ons & libraries
Get Adagene Inc Fundamental Data
Adagene Inc Fundamental data includes:
- Net Revenue: 103 K
- EBITDA: -32 765 248
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-03
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adagene Inc News
New
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Adagene Inc. ADAG announced that the FDA has granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126). The designation was granted to muzastotug in com...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Adagene Inc. Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE...
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a lice...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
